- Home
- TPG vs PTGX Comparison
TPG vs PTGX Comparison
Compare TPG & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TPG | PTGX |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United States | United States |
| Employees | 1900 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.2B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | TPG | PTGX |
|---|---|---|
| Price | $38.49 | $103.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 12 |
| Target Price | $63.13 | ★ $106.67 |
| AVG Volume (30 Days) | ★ 3.3M | 807.6K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $867.86 |
| Revenue Next Year | $19.04 | N/A |
| P/E Ratio | $106.82 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.95 | $39.60 |
| 52 Week High | $70.38 | $107.84 |
Technical Indicators
Market Signals| Indicator | TPG | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 33.95 | 62.28 |
| Support Level | N/A | $76.63 |
| Resistance Level | $42.17 | N/A |
| Average True Range (ATR) | 1.69 | 4.88 |
| MACD | 0.34 | 0.13 |
| Stochastic Oscillator | 29.50 | 76.48 |
Price Performance
Historical ComparisonAbout TPG TPG Inc.
TPG Inc is an alternative asset management firm. It invests across five multi-product platforms, namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company invests across a broadly diversified set of strategies, including private equity, impact, credit, real estate, market solutions, innovation, and inclusion.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.